Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOK965)

Drug Name
Prulifloxacin Drug Info
Synonyms
123447-62-1; NM441; NM 441; NM-441; Prulifloxacin (hydrochloride); 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; NCGC00164615-01; Quisnon; DSSTox_CID_26480; DSSTox_RID_81651; DSSTox_GSID_46480; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-; 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; Prulifloxacin [INN]; Pruvel; Sword; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; CCRIS 7686; CAS-123447-62-1; Pufloxacin dioxolil; 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; MLS006011767; CHEMBL422648; NAD-441A; OPT-99; SCHEMBL1650794; DTXSID0046480; CHEBI:32071; AOB5600; BCP12727; HY-B0024; Tox21_112235; BBL034010; MFCD00864847; s2071; STK626148; AKOS005559236; Prulifloxacin (NM441, AF 3013); Tox21_112235_1; AC-2012; DB11892; MCULE-8435182996; SB18983; NCGC00164615-02; NCGC00164615-03; (+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate; AK144730; AS-13607; I926; SMR000046722; AB0013936; FT-0651733; P2058; Prulifloxacin 100 microg/mL in Acetonitrile; K-1771; 447P621; Prulifloxacin, >=98% (perchloric acid titration); SR-01000872596; Prulifloxacin, Antibiotic for Culture Media Use Only; Q-101929; Q3924793; SR-01000872596-1; BRD-A92341659-001-01-6
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [1]
Cross-matching ID
PubChem CID
65947
ChEBI ID
CHEBI:32071
CAS Number
CAS 123447-62-1
TTD Drug ID
DMOK965

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial DNA gyrase (Bact gyrase)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [4]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [5]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [5]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [5]
Norfloxacin DMIZ6W2 Acute gonococcal cervicitis Approved [5]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [6]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [5]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [5]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [7]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Bacterial DNA topoisomerase 4A (Bact parC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pazufloxacin DMHXTAQ Conjunctivitis 9A60 Phase 3 [9]
Sitafloxacin DMTV5XC Escherichia coli infection 1A03 Phase 2/3 [10]
VB 1953 DM0YWQ4 Acne vulgaris ED80 Phase 2 [11]
JNJ-32729463 DMQD1GN Community-acquired pneumonia CA40.Z Phase 2 [12]
TNP-2092 DM8DZKI Skin and skin-structure infection 1F28-1G0Z Phase 2 [13]
A-62824 DMJ6IMZ Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Serum paraoxonase/arylesterase 1 (PON1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Loteprednol Etabonate DM8QTJI Eye inflammation 9A02 Approved [15]
RTR-003632 DM45NHF N. A. N. A. Phase 2 [16]
PARAOXON DMN4ZKC Discovery agent N.A. Investigative [16]
gamma-butyrolactone DMDCZWY Discovery agent N.A. Investigative [16]
Coumaranone DM7TCPG N. A. N. A. Investigative [16]
Dihydrocoumarin DMGLX1R N. A. N. A. Investigative [16]
Gamma-thiobutyrolactone DM83HUI N. A. N. A. Investigative [16]
Homogentisic acid DMQD0YW N. A. N. A. Investigative [16]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [17]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [17]
Hydroxyflutamide DMGIZF5 Prostate cancer 2C82.0 Approved [17]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [18]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [19]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [20]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [3]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [21]
Selenium DM25CGV N. A. N. A. Approved [22]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Inhibitor [1]
Bacterial DNA topoisomerase 4A (Bact parC) TTFK8YB PARC_ECOLI Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Serum paraoxonase/arylesterase 1 (PON1) Main DME DESDN74 PON1_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Protein Interaction/Cellular Processes [3]

References

1 Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
2 Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
3 Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
4 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9 Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
10 Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
11 Clinical pipeline report, company report or official report of Vyome Therapeutics.
12 Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
13 Clinical pipeline report, company report or official report of TenNor Therapeutics.
14 Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent anti... Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6.
15 Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89.
16 Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
17 TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
18 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
19 Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
20 Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
21 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
22 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
23 Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.